The Warburg effect and drug resistance

British Journal of Pharmacology

Volumn 173, Issue 6, 2016, Pages 970-979

  Bhattacharya, Bhaskar ^a   Mohd Omar, Mohd Feroz ^b   Soong, Richie ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; 7 HYDROXYSTAUROSPORINE; CARBOPLATIN; FLUOROURACIL; FRUCTOSE 2,6 BISPHOSPHATE; GEMCITABINE; GLUCOSE TRANSPORTER; GLYCOLYTIC ENZYME; HEAT SHOCK TRANSCRIPTION FACTOR 1; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PKM2 PROTEIN; PROTEIN KINASE B; PROTEIN KINASE LKB1; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SORAFENIB; UNCLASSIFIED DRUG; GLUCOSE;

CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELLULAR STRESS RESPONSE; DNA DAMAGE; DRUG EFFICACY; DRUG RESISTANCE; DRUG SCREENING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HYPOGLYCEMIA; ONCOGENE MYC; ONCOGENE RAS; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WARBURG EFFECT; ANIMAL; HUMAN; METABOLISM; NEOPLASM; ONCOGENE; PRECLINICAL STUDY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS; ONCOGENES;

EID: 84960082836     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13422     Document Type: Review

References (107)

1. Abraham RT, (2004). mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279: 299-319.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979-6023.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729-5143.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
5. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110-6202.
6. Altman BJ, Rathmell JC, (2012). Metabolic stress in autophagy and cell death pathways. Cold Spring Harb Perspect Biol 4: a008763.
7. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, et al., (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
8. Bhattacharya B, Low SH, Soh C, Kamal Mustapa N, Beloueche-Babari M, Koh KX, et al., (2014). Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. Br J Pharmacol 171: 3255-3267.
9. Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M, (2010). Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett 289: 246-253.
10. Buller CL, Heilig CW, Brosius FC 3rd, (2011). GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am J Physiol Renal Physiol 301: F588-F596.
11. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, et al., (2008). A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 295: C836-C843.
12. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al., (2007). Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59: 495-505.
13. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, et al., (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19: 4125-4133.
14. Dai C, Whitesell L, Rogers AB, Lindquist S, (2007). Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130: 1005-1018.
15. Dang CV, Le A, Gao P, (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483.
16. Denko NC, (2008). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713.
17. Diaz-Ruiz R, Rigoulet M, Devin A, (2011). The Warburg and Crabtree effects: on the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta 1807: 568-576.
18. Duffy A, Le J, Sausville E, Emadi A, (2014). Autophagy modulation: a target for cancer treatment development. Cancer Chemother Pharmacol. doi: 10.1007/s00280-014-2637-z.
19. Eickelberg O, Seebach F, Riordan M, Thulin G, Mann A, Reidy KH, et al., (2002). Functional activation of heat shock factor and hypoxia-inducible factor in the kidney. J Am Soc Nephrol 13: 2094-2101.
20. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al., (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
21. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al., (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819.
22. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al., (2013). Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 16: 1373-1382.
23. Foster R, Griffin S, Grooby S, Feltell R, Christopherson C, Chang M, et al., (2012). Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS One 7: e45061.
24. Fu Y, Lee AS, (2006). Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5: 741-744.
25. Ganapathy V, Thangaraju M, Prasad PD, (2009). Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29-40.
26. Gatenby RA, Gillies RJ, (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
27. Gatenby RA, Gillies RJ, (2007). Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39: 1358-1366.
28. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL, (2004). Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 4: 449-457.
29. Goodman C, (2012). Metabolism: a Warburg shakeup. Nat Chem Biol 8: 20.
30. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ, (2004). Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10: 6661-6668.
31. Green DR, Chipuk JE, (2006). p53 and Metabolism: inside the TIGAR. Cell 126: 30-32.
32. Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y, et al., (2011). Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 137: 65-72.
33. Harris MH, Vander Heiden MG, Kron SJ, Thompson CB, (2000). Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 20: 3590-3596.
34. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN, (2010). Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795.
35. Hirschhaeuser F, Sattler UG, Mueller-Klieser W, (2011). Lactate: a metabolic key player in cancer. Cancer Res 71: 6921-6925.
36. Hoelder S, Clarke PA, Workman P, (2012). Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6: 155-176.
37. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, et al., (2012). K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22: 399-412.
38. Hwang JH, Kim JY, Cha MR, Ryoo IJ, Choo SJ, Cho SM, et al., (2008). Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator. J Cell Physiol 215: 243-250.
39. Icard P, Kafara P, Steyaert JM, Schwartz L, Lincet H, (2014). The metabolic cooperation between cells in solid cancer tumors. Biochim Biophys Acta 1846: 216-225.
40. Jang M, Kim SS, Lee J, (2013). Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 45: e45.
41. Jeon SM, Chandel NS, Hay N, (2012). AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-665.
42. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al., (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
43. Jung CH, Ro SH, Cao J, Otto NM, Kim DH, (2010). mTOR regulation of autophagy. FEBS Lett 584: 1287-1295.
44. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al., (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11: 2785-2808.
45. Kim Y, Lin Q, Glazer PM, Yun Z, (2009). Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 9: 425-434.
46. Kleman AM, Yuan JY, Aja S, Ronnett GV, Landree LE, (2008). Physiological glucose is critical for optimized neuronal viability and AMPK responsiveness in vitro. J Neurosci Methods 167: 292-301.
47. Ko YH, Pedersen PL, Geschwind JF, (2001). Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173: 83-91.
48. Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS, et al., (2012). Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 423: 38-44.
49. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al., (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
50. Le Calve B, Rynkowski M, Le Mercier M, Bruyere C, Lonez C, Gras T, et al., (2010). Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 12: 727-739.
51. Lee DC, Sohn HA, Park ZY, Oh S, Kang YK, Lee KM, et al., (2015). A lactate-induced response to hypoxia. Cell 161: 595-609.
52. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al., (2007). The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224.
53. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al., (2012). A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11: 1672-1682.
54. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, et al., (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833-843.
55. Lobo NA, Shimono Y, Qian D, Clarke MF, (2007). The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
56. Ma W, Sung HJ, Park JY, Matoba S, Hwang PM, (2007). A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 39: 243-246.
57. Martinez-Balibrea E, Plasencia C, Gines A, Martinez-Cardus A, Musulen E, Aguilera R, et al., (2009). A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 8: 771-778.
58. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al., (2011). Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 10: 1271-1286.
59. Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R, (2013). Resistance to dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget 4: 2550-2566.
60. Martins AS, Davies FE, Workman P, (2012). Inhibiting the molecular evolution of cancer through HSP90. Oncotarget 3: 1054-1056.
61. Mathupala SP, Ko YH, Pedersen PL, (2006). Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786.
62. Mathupala SP, Ko YH, Pedersen PL, (2010). The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797: 1225-1230.
63. McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M, (2012). Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 119: 4686-4697.
64. Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, et al., (2013). INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun 440: 137-142.
65. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, et al., (2000). ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 468: 53-58.
66. Morten KJ, Badder L, Knowles HJ, (2013). Differential regulation of HIF-mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts. J Pathol 229: 755-764.
67. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C, (2002). ERK and calcium in activation of HIF-1. Ann N Y Acad Sci 973: 448-453.
68. Nihira K, Miki Y, Iida S, Narumi S, Ono K, Iwabuchi E, et al., (2014). An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. J Pathol 234: 277-288.
69. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, et al., (2008). Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14: 458-470.
70. Onozuka H, Tsuchihara K, Esumi H, (2011). Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci 102: 975-982.
71. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al., (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-21800.
72. Page TJ, Sikder D, Yang L, Pluta L, Wolfinger RD, Kodadek T, et al., (2006). Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol Biosyst 2: 627-639.
73. Pastorino JG, Shulga N, Hoek JB, (2002). Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277: 7610-7618.
74. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, et al., (2014). Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J 33: 1454-1473.
75. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
76. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A, (2006). Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471-479.
77. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P, (2011). Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2: 49.
78. Rohwer N, Cramer T, (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.
79. Ru P, Williams TM, Chakravarti A, Guo D, (2013). Tumor metabolism of malignant gliomas. Cancer 5: 1469-1484.
80. Ruetz S, Gros P, (1994). A mechanism for P-glycoprotein action in multidrug resistance: are we there yet? Trends Pharmacol Sci 15: 260-263.
81. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, et al., (2006). Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5: 1197-1208.
82. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-Ya K, et al., (2009). Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 69: 4225-4234.
83. Schneider A, Younis RH, Gutkind JS, (2008). Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 10: 1295-1302.
84. Seton-Rogers S, (2011). Cancer metabolism: feed it forward. Nat Rev Cancer 11: 461-461.
85. Shackelford DB, Shaw RJ, (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
86. Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, et al., (2013). Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 108: 72-81.
87. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, et al., (2010). Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 101: 1447-1453.
88. Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, et al., (2009). Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 30: 2182-2192.
89. Solaini G, Sgarbi G, Baracca A, (2011). Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 1807: 534-542.
90. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al., (2013). Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4: e838.
91. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al., (2011). Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108: 4129-4134.
92. Teperino R, Amann S, Bayer M, McGee SL, Loipetzberger A, Connor T, et al., (2012). Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 151: 414-426.
93. Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, et al., (2015). The multikinase inhibitor sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep 5: 9149.
94. Thorens B, Mueckler M, (2010). Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 298: E141-E145.
95. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y, et al., (2006). Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 98: 1462-1473.
96. Vander Heiden MG, Cantley LC, Thompson CB, (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324: 1029-1033.
97. Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N, (2013). From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol 45: 106-113.
98. Vinogradov S, Wei X, (2012). Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7: 597-615.
99. Vyas AK, Koster JC, Tzekov A, Hruz PW, (2010). Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 285: 36395-36400.
100. Wang YD, Li SJ, Liao JX, (2013). Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat 12: 525-535.
101. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al., (2008). Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105: 18782-18787.
102. Workman P, (2004). Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51.
103. Xie JM, Li B, Yu HP, Gao QG, Li W, Wu HR, et al., (2014). TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy. Cancer Res 74: 5127-5138.
104. Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK, et al., (2004). Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 108: 532-539.
105. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al., (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, NY) 325: 1555-1559.
106. Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, et al., (2011a). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71: 4585-4597.
107. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, et al., (2011b). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71: 4585-4597.